Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Live Birth After Fresh Embryo Transfer vs Elective Embryo Cryopreservation/Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome Undergoing IVF: A Multi-center Prospective Randomized Clinical Trial
Brief Summary: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of childbearing age. However, the optimal infertility treatment for PCOS patients is still a matter of controversy. Despite producing more follicles and more oocytes than other women undergoing controlled ovarian hyperstimulation during an IVF cycle, women with PCOS have comparable or lower pregnancy rates. Additionally women with PCOS patients undergoing IVF have a higher risk of developing ovarian hyperstimulation syndrome (OHSS), which may be aggravated by pregnancy after an embryo transfer in a fresh cycle. Further women with PCOS are thought to have higher rates of later pregnancy complications including spontaneous abortion, pre-eclampsia, and preterm labor that may be related to impaired implantation in the superovulated endometrium. We propose a randomized clinical trial of elective embryo cryopreservation followed by a programmed cycle of endometrial preparation and frozen embryo transfer (FET) compared to fresh embryo transfer in women with PCOS undergoing in vitro fertilization (IVF).


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: Estrogen pre-treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17beta-estradiol | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 17beta-estradiol; Assigned to Arm(s): Estrogen pre-treatment
C: Arm Label: NuvaRing; Type: EXPERIMENTAL; Interventions: Drug: NuvaRing | Arm Label: Combined oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: marvelon | Intervention Type: DRUG; Name: NuvaRing; Assigned to Arm(s): NuvaRing | Intervention Type: DRUG; Name: marvelon; Assigned to Arm(s): Combined oral contraceptive pill
D: Arm Label: 150 µg Corifollitropin Alfa; Type: EXPERIMENTAL; Interventions: Drug: Corifollitropin alfa, Drug: Placebo RecFSH / follitropin beta, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Arm Label: 200 IU recFSH; Type: ACTIVE_COMPARATOR; Interventions: Biological: RecFSH / Follitropin beta (Days 1 to 7), Drug: Placebo Corifollitropin alfa, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Intervention Type: DRUG; Name: Corifollitropin alfa; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 1 to 7); Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo Corifollitropin alfa; Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo RecFSH / follitropin beta; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 8 to hCG); Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: DRUG; Name: Ganirelix; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: hCG; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: Progesterone; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH

Answer: A